Alzheimer's Disease Trial, Recruiting NCT05614310 Sponsor: University of Aberdeen Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05614310
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Development phase – Control participants:

  • People who are over 18 years old
  • People who are willing to give their agreement to take part in the study
  • People who do not have any concerns or complaints about their memory

Clinical phase – Patients:

  • People who are 65 years old or older
  • People who are able to give their agreement to take part in the study
  • People who have been formally diagnosed with Alzheimer's disease by a mental health team

Clinical phase – Control participants:

  • People who are 65 years old or older
  • People who are able to give their agreement to take part in the study
  • People who have scored within the normal range on two standard memory and thinking tests (confirm with trial site for details on these tests)
  • People who do not have any concerns or complaints about their memory

Who may not be able to join:

  • People with a history of diabetes
  • People who have had a major stroke (note: mini-strokes or certain smaller types of stroke may still be acceptable — confirm with trial site)
  • People who cannot have an MRI scan, for example due to having an implanted heart device
  • People with a family history of Alzheimer's disease, due to possible genetic factors
  • People with advanced Alzheimer's disease who are not able to give their own agreement to participate
  • People who are pregnant (for the development phase)
  • People who are unable to read or speak English

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gordon Waiter, PhD, University of Aberdeen

Phone: +44 (0)1224 438356

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Aberdeen
Registry
ClinicalTrials.gov
Start date
15 November 2022
Est. completion
31 December 2025

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

PET glucose measurement; CEST-MRI glucose measurement; Sensitivity and specificity of CEST-MRI glucose measurements; Repeatability of CEST-MRI glucose measurement

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov